Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. SK Biopharmaceuticals Co., Ltd.
  6. News
  7. Summary
    A326030   KR7326030004

SK BIOPHARMACEUTICALS CO., LTD.

(A326030)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SK Biopharmaceuticals Co., Ltd. Reports Consolidated Earnings Results for the First Quarter of 2021

05/11/2021 | 09:30pm EDT

SK Biopharmaceuticals Co., Ltd. reported consolidated earnings results for the first quarter of 2021. The company reported revenue based on consolidated financial statements reached KRW 140 billion, an increase of 770% quarter-on- quarter, including milestone sales of KRW 124.5 billion. The company recorded operating profit of KRW 75.9 billion, turning a profit quarter-on- quarter.


ę S&P Capital IQ 2021
All news about SK BIOPHARMACEUTICALS CO., LTD.
09/08SK Biopharmaceuticals' New Drugs Draw Favorable Reception in North America, Europe
MT
09/08KOSPI COMPOSITE INDEX : South Korean Stocks Fall for a Second Straight Session; SK Biophar..
MT
09/03KOSPI COMPOSITE INDEX : South Korean Stocks Close in Green on Foreign Buying Ahead of US L..
MT
09/02SK Biopharmaceuticals Expands Overseas Market for Narcolepsy Drug to Canada
MT
09/02SK Biopharmaceuticals Rolls Out Narcolepsy Treatment Drug in Canada
MT
06/17MARKET CHATTER : SK Biopharmaceuticals Launches Epilepsy Drug in Europe
MT
05/11SK Biopharmaceuticals Co., Ltd. Reports Consolidated Earnings Results for the First Qua..
CI
04/02SK IE Technology to Go Public on KOSPI in May
MT
04/01SK BIOPHARMACEUTICALS : ONTOZRY (Cenobamate) receives European Commission approval
AQ
04/01EC Clears SK Biopharmaceuticals' Epilepsy Drug Cenobamate for Sale in Europe
MT
More news
Financials
Sales 2021 224 B 0,19 B 0,19 B
Net income 2021 -28,8 B -0,02 B -0,02 B
Net cash 2021 359 B 0,30 B 0,30 B
P/E ratio 2021 -287x
Yield 2021 -
Capitalization 8 380 B 7 094 M 7 106 M
EV / Sales 2021 35,8x
EV / Sales 2022 23,2x
Nbr of Employees -
Free-Float 33,7%
Chart SK BIOPHARMACEUTICALS CO., LTD.
Duration : Period :
SK Biopharmaceuticals Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SK BIOPHARMACEUTICALS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 107 000,00 KRW
Average target price 131 857,14 KRW
Spread / Average Target 23,2%
EPS Revisions
Managers and Directors
Jeong-Woo Cho President, Chief Executive Officer & Director
Young-Ju Bang Independent Director
Hae-Young Ahn Independent Director
Min-Seop Song Independent Director
Geun-Joo Hwang Non-Executive Director
Sector and Competitors